Wild Biotech
Tel Aviv, Israel· Est.
AI‑driven discovery of miniprotein therapeutics from wild microbial DNA for immune and metabolic diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑driven discovery of miniprotein therapeutics from wild microbial DNA for immune and metabolic diseases.
ImmunologyMetabolismCardiovascular
Technology Platform
AI‑driven mining of a 200 M+ microbial gene database from extreme animal biodiversity, combined with synthetic biology screening to generate stable, orally bioavailable miniprotein and peptide therapeutics.
Opportunities
Leveraging a uniquely diverse biodiversity database and AI to create oral biologic‑like therapeutics could unlock high‑value targets in immunology and metabolism, attracting partnership or licensing deals.
Risk Factors
Unproven miniprotein modality, regulatory hurdles for novel peptide scaffolds, and the need for substantial capital to advance multiple candidates through clinical development.
Competitive Landscape
While other firms develop peptide therapeutics, Wild’s extensive wild‑derived scaffold library and AI‑driven discovery differentiate it, though it competes with established peptide platforms and emerging AI‑driven drug discovery companies.